Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.62 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | PTPRB | P23467 | 1/20 | 0.57 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10608486 | 0.87 | KMT2A (0.71) | MEN1KMT2ALMNACYP1A2TDP1 | |
| Acetaminophen SCHEMBL7785413 | 0.87 | MAPT (0.54) | MEN1KMT2ALMNACYP1A2TDP1 | |
| SCHEMBL12810424 | 0.86 | MAPT (0.61) | MEN1KMT2ALMNACYP1A2TDP1 | |
| SCHEMBL12678535 | 0.84 | MEN1 (0.67) | MEN1KMT2ALMNACYP1A2TDP1 | |
| SCHEMBL3048962 | 0.84 | GPR174 (0.72) | MEN1KMT2ALMNACYP1A2TDP1 | |
| SCHEMBL16270232 | 0.84 | SMN1; SMN2 (0.65) | MEN1KMT2AMAPTMAPK1ALDH1A1 | |
| SCHEMBL11888597 | 0.83 | NPC1 (0.76) | MEN1KMT2ALMNACYP1A2TDP1 | |
| SCHEMBL11111056 | 0.83 | ALDH1A1 (0.80) | MEN1KMT2ALMNACYP1A2TDP1 | |
| SCHEMBL11366781 | 0.83 | ALDH1A1 (0.58) | MEN1KMT2ALMNACYP1A2TDP1 | |
| SCHEMBL25195104 | 0.83 | MAPT (0.66) | MEN1KMT2AMAPTMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113248596-A | Artificial antigen and antibody capable of simultaneously detecting acetaminophen and phenacetin, and preparation method and application thereof | 华南农业大学 | 2021-08-13 | — | — | CN | claimed |
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | claimed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | claimed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | claimed |
| EP-1165064-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | City of Hope (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059875-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | CITY OF HOPE (US) | 2000-10-12 | — | — | WO | claimed |
| EP-4115885-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING BAY 86-5277 AND SALTS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS AND HYPERINFLAMMATION | Charité - Universitätsmedizin Berlin (DE) | 2023-01-11 | — | — | EP | disclosed |
| CN-113248596-B | Artificial antigen and antibody capable of simultaneously detecting acetaminophen and phenacetin, and preparation method and application thereof | 华南农业大学 | 2022-12-16 | — | — | CN | disclosed |
| CN-113248596-A | Artificial antigen and antibody capable of simultaneously detecting acetaminophen and phenacetin, and preparation method and application thereof | 华南农业大学 | 2021-08-13 | — | — | CN | disclosed |
| US-20190083482-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190083482-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2019-03-21 | — | — | US | disclosed |
| EP-3406607-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1212299-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca UK Limited (GB) | 2002-06-12 | — | — | EP | disclosed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | disclosed |
| WO-2001014333-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-03-01 | — | — | WO | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083482-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | MEN1 1329/4885KMT2A 58/4885LMNA 2468/4885 |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | MEN1 1238/4885KMT2A 35/4885LMNA 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.